相似文献
1
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.
Blood Adv. 2019 Aug 27;3(16):2487-2490. doi: 10.1182/bloodadvances.2019000466.
2
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13.
3
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
Leukemia. 2021 Jan;35(1):255-258. doi: 10.1038/s41375-020-0834-9. Epub 2020 Apr 21.
4
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Front Immunol. 2021 Mar 5;12:609421. doi: 10.3389/fimmu.2021.609421. eCollection 2021.
5
BCMA-targeting approaches for treatment of multiple myeloma.
Panminerva Med. 2021 Mar;63(1):28-36. doi: 10.23736/S0031-0808.20.04121-X. Epub 2020 Sep 21.
6
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):537-544. doi: 10.1016/j.clml.2019.08.002. Epub 2019 Aug 7.
7
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2.
8
Multiple Myeloma: The CAR T-cell Therapy Landscape.
Cancer Discov. 2020 Feb;10(2):OF6. doi: 10.1158/2159-8290.CD-ND2019-015. Epub 2020 Jan 8.
9
Targeting BCMA in Multiple Myeloma.
Curr Hematol Malig Rep. 2021 Oct;16(5):367-383. doi: 10.1007/s11899-021-00639-z. Epub 2021 Aug 25.
10
Antibody-Based Treatment Approaches in Multiple Myeloma.
Curr Hematol Malig Rep. 2021 Apr;16(2):183-191. doi: 10.1007/s11899-021-00624-6. Epub 2021 Mar 17.
引用本文的文献
1
CAR T-cell therapy to treat multiple myeloma: current state and future directions.
Cancer Metastasis Rev. 2024 Dec 3;44(1):14. doi: 10.1007/s10555-024-10219-1.
2
T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment.
Blood Cancer Discov. 2024 Nov 1;5(6):388-399. doi: 10.1158/2643-3230.BCD-24-0124.
3
Challenges and strategies associated with CAR-T cell therapy in blood malignancies.
Exp Hematol Oncol. 2024 Feb 24;13(1):22. doi: 10.1186/s40164-024-00490-x.
4
Options at the time of relapse after anti-BCMA therapy.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):450-458. doi: 10.1182/hematology.2023000445.
5
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.
Cancer Immunol Immunother. 2023 Dec;72(12):3931-3937. doi: 10.1007/s00262-023-03559-4. Epub 2023 Nov 4.
6
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.
Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.
7
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
Int J Mol Sci. 2022 Dec 30;24(1):645. doi: 10.3390/ijms24010645.
8
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Front Oncol. 2022 Nov 15;12:1026251. doi: 10.3389/fonc.2022.1026251. eCollection 2022.
9
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Haematologica. 2023 Apr 1;108(4):958-968. doi: 10.3324/haematol.2020.266841.
10
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.
Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628.
本文引用的文献
1
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
2
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
3
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.
4
Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.
Leuk Res. 2018 Aug;71:106-111. doi: 10.1016/j.leukres.2018.07.015. Epub 2018 Jul 18.
5
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
6
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.
7
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.
8
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.
9
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Br J Haematol. 2016 Sep;174(6):911-22. doi: 10.1111/bjh.14145. Epub 2016 Jun 17.
10
Chimeric antigen receptor T cells for sustained remissions in leukemia.
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
Zotero 插件